

AMENDMENTS TO THE CLAIMS

1. (previously presented) A crystal of ACE protein.
2. (previously presented) A crystal according to claim 1 wherein the ACE protein is underglycosylated.
3. (previously presented) A crystal according to claim 2 wherein the ACE protein is underglycosylated by removing one or more glycosylation sites and/or one or more partially glycosylated sites.
4. (currently amended) A crystal according to claim 3 wherein the underglycosylated ACE protein comprises a mutation at amino acid 337 or amino acid ~~90,109,155,337 and 586 of SEQ ID No 2~~90, 109, 155, 337 and 586 of SEQ ID No 2.
5. (previously presented) A crystal according to claim 1 comprising atoms arranged in a spatial relationship represented by at least a portion of the structure coordinates of Table A or Table B.
6. (currently amended) A crystal according to claim 1 wherein the crystal belongs to the space group $P2_12_12_1$ or wherein the crystal has the unit cell dimensions: $a=56.47 \text{ \AA}$, $b=84.90 \text{ \AA}$ and $c=133.99 \text{ \AA}$.
7. (canceled)
8. (previously presented) A crystal according to claim 1 wherein the crystal is a crystal of human ACE protein.

9. (previously presented) A crystal according to claim 1 wherein the crystal further comprises an entity bound to the ACE protein or a portion thereof.

10. (currently amended) A crystal according to claim 9 wherein the entity is bound to the ACE protein or a portion thereof by contacting one or more residues of the ACE protein selected from : ~~His384, Ala385, Lys542, Tyr551, Tyr554, Glu415~~ His384, Ala385, Lys542, Tyr551, Tyr554, Glu415 and His544.

11. (previously presented) A crystal according to claim 9 wherein the entity modulates the activity of ACE.

12. (previously presented) A crystal according to claim 11 wherein the entity is an inhibitor of ACE.

13. (previously presented) A crystal according to claim 12 wherein the inhibitor of ACE is lisinopril or a derivative thereof.

14. (previously presented) A crystal according to claim 13 comprising atoms arranged in a spatial relationship represented by at least a portion of the structure coordinates of Table B.

15. (previously presented) A method of preparing a crystal of ACE protein comprising the steps of :

- (a) culturing host cells comprising an underglycosylated ACE protein;
- (b) purifying the underglycosylated ACE protein; and
- (c) crystallising the underglycosylated ACE protein.

16. (previously presented) A method according to claim 15 wherein the ACE protein is underglycosylated by removing one or more glycosylation sites and/or one or more partially glycosylated sites.

17. (currently amended) A method according to claim 15 wherein the underglycosylated ACE protein comprises a mutation at amino acid 337 of SEQ ID No 2 or amino acids ~~90, 109, 155, 337~~ 90, 109, 155, 337 and 586 of SEQ ID No 2.

18. (previously presented) A method according claim 15 wherein the ACE protein is crystallised using about 10 mM HEPES and about 0. 1% PMSF with an equal volume of a reservoir solution containing about 15 % PEG 4000, about 50 mM $\text{CH}_3\text{COONa} \cdot 3\text{H}_2\text{O}$ pH 4.7 and about 10 μM $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$.

19. (previously presented) A method according claim 15 wherein the crystal that is prepared has a structure defined by at least a portion of the structure coordinates of Table A.

20. (currently amended) A method according claim 15 wherein the crystal belongs to the space group $\text{P}2_12_12_1$ or wherein the crystal has the unit cell dimensions: $a=56.47 \text{ \AA}$, $b=84.90 \text{ \AA}$ and $c=133.99 \text{ \AA}$.

21. (canceled)

22. (previously presented) A method according to claim 15 wherein the ACE protein is human ACE protein.

23. (previously presented) A method according to claim 15 wherein the ACE protein is crystallised in the presence of an entity.

24. (previously presented) A method according to claim 23 wherein the entity is a modulator of ACE.

25. (previously presented) A method according to claim 24 wherein the entity is an inhibitor of ACE.

26. (previously presented) A method according to claim 25 wherein the inhibitor of ACE is lisinopril or a derivative thereof.

27. (previously presented) A method according to claim 26 wherein the crystal that is prepared has a structure defined by at least a portion of the structure coordinates of Table B.

28-35. (canceled)

36. (withdrawn-currently amended) A method of screening for a modulator of ACE wherein the method comprises the use of a crystal according to claim 1 ~~and according to claim 28~~ wherein the ACE modulator is useful in the prevention and/or treatment of an ACE related disorder.

37. (withdrawn-previously presented) A method according to claim 36 wherein the ACE related disorder is hypertension.

38-44. (canceled)

45. (withdrawn-currently amended) A method of preventing and/or treating an ACE related disorder comprising administering a modulator of ACE ~~according to claim 42~~ wherein said modulator of ACE is capable of causing a beneficial preventative and/or therapeutic effect and wherein said modulator is identified by a screening method that comprises the use of a crystal according to claim 1.

46-60. (canceled)